Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01401062 · ClinicalTrials.gov registry record · Phase 2
Fresolimumab and Radiotherapy in Metastatic Breast Cancer
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT01401062 is a Phase 2 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 23 participants.
The verdict
NCT01401062, a Phase 2 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to test safety of combining fresolimumab and local radiotherapy and to see if the combination can achieve tumor regression.
Interventions
- RADIATION Radiation Therapy
- DRUG Fresolimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2011-07 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01401062
The ClinicalTrials.gov registry entry for NCT01401062 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Radiation Therapy is the first listed.
NCT01401062 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01401062 about?
NCT01401062 is a clinical study titled "Fresolimumab and Radiotherapy in Metastatic Breast Cancer". The purpose of this study is to test safety of combining fresolimumab and local radiotherapy and to see if the combination can achieve tumor regression.
What is the current status of trial NCT01401062?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2011-07. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01401062?
The interventions under investigation include: Radiation Therapy (RADIATION), Fresolimumab (DRUG).
Who is sponsoring clinical trial NCT01401062?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.